PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy represent an effective and tolerable regimen for advanced ICC in a multicenter retrospective real-world study. The gene discussed is PDCD1; the disease is intrahepatic cholangiocarcinoma.